A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Debio 4228 (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Debiopharm
Most Recent Events
- 30 May 2025 Planned number of patients changed from 60 to 66.
- 30 May 2025 Planned End Date changed from 1 Apr 2026 to 1 Jan 2027.
- 30 May 2025 Planned primary completion date changed from 1 Mar 2026 to 1 Dec 2026.